Etoricoxib (hydrochloride)

Etoricoxib hydrochloride (MK-0663 hydrochloride) is a synthetic nonsteroidal anti-inflammatory drug with cyclooxygenase-2 inhibitory activity. Etoricoxib hydrochloride can inhibit the conversion of arachidonic acid to prostaglandins, thereby reducing inflammation and pain. Etoricoxib hydrochloride is used to inhibit osteoarthritis and has anti-inflammatory and bone remodeling effects. The formulation of etoricoxib hydrochloride is prepared by emulsion solvent evaporation technology and exhibits good cell compatibility and enhanced alkaline phosphatase activity[1].

Product Specifications

CAS Number

[202409-40-3]

Product Name Alternative

MK-0663 (hydrochloride) ; L-791456 (hydrochloride)

UNSPSC

12352005

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/etoricoxib-hydrochloride.html

Smiles

O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O.[H]Cl

Molecular Formula

C18H16Cl2N2O2S

Molecular Weight

395.30

References & Citations

[1]Riendeau D, et al.Etoricoxib (MK-0663) : preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296 (2) :558-66.|[2]Kunak CS, et al. The Effect of Etoricoxib on Hepatic Ischemia-Reperfusion Injury in Rats. Oxid Med Cell Longev. 2015;2015:598162.|[3]Tanwar L, et al. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11 (5) :1329-33.|[4]Etoricoxib-loaded bio-adhesive hybridized polylactic acid-based nanoparticles as an intra-articular injection for the treatment of osteoarthritis